博晖创新：近日，公司控股孙公司博晖生物制药股份有限公司与北京百晖生物科技有限公司联合申报的冻干人用狂犬病疫苗（人二倍体细胞），获得国家药监局出具的《药物临床试验批准通知书》，同意开展临床试验。复宏汉霖：近日，公司自主研发的汉贝泰®（贝伐珠单抗注射液）的生物制品许可申请（BLA）已获美国FDA受理。此次申请涉及的适应症包括转移性结直肠癌、联合卡铂和紫杉醇一线治疗不可切除的局部晚期、复发性或转移性...
Source Link博晖创新：近日，公司控股孙公司博晖生物制药股份有限公司与北京百晖生物科技有限公司联合申报的冻干人用狂犬病疫苗（人二倍体细胞），获得国家药监局出具的《药物临床试验批准通知书》，同意开展临床试验。复宏汉霖：近日，公司自主研发的汉贝泰®（贝伐珠单抗注射液）的生物制品许可申请（BLA）已获美国FDA受理。此次申请涉及的适应症包括转移性结直肠癌、联合卡铂和紫杉醇一线治疗不可切除的局部晚期、复发性或转移性...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.